...
首页> 外文期刊>Molecular diagnosis & therapy >Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer.
【24h】

Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer.

机译:端粒酶活性作为宫颈上皮内瘤变和宫颈癌的印度女性的一种肿瘤标志物。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND OBJECTIVES: Cervical cancer is the most common cancer in Indian women and is a leading cause of death in women worldwide. Cervical cancer develops from pre-neoplastic cervical intraepithelial neoplasia (CIN). This study was conducted to evaluate telomerase activity as a tumor marker for the detection of cancer in patients with CIN and cervical cancer. The results were compared with human papillomavirus (HPV) status, clinical staging, and histopathologic studies. METHODS: Telomerase activity was detected using the PCR-based telomeric repeat amplification protocol (TRAP) assay in cervical tissues collected by routine punch biopsy from the uterine cervix of patients with suspected cervical cancer. High-risk (HR) HPV-16 and -18 status was determined in all the study groups, including controls. A total of 125 patients (including 50 patients with CIN and 75 patients with cervical cancer [including nine patients with adeno-squamous disease]) and 22 control subjects were studied. The sensitivityand specificity for detecting CIN and cervical cancer were calculated. RESULTS: Patients with grade I, II, and III CIN showed 17%, 33%, and 57% positivity for telomerase, respectively. In patients with cervical cancer, those at early clinical stages (Ia-IIb) showed 68% positivity and those at later clinical stages showed 92% positivity for telomerase activity. In the present study, telomerase positivity correlated significantly with the detection of HR HPV-16 and -18 (p < 0.001). As a diagnostic test, none of the described analyses combined a sensitivity of > or =90% with a specificity of > or =90%, except in patients with advanced cancer when telomerase activity was used as a diagnostic test. CONCLUSION: Our findings suggest that telomerase activation is a relatively early event in cervical carcinogenesis and correlates with the grade of cervical lesion, HR-HPV status (16 and 18 subtypes), and clinical staging. Hence, these associations suggest it as a possible target for detection of cervical cancer.
机译:背景与目的:宫颈癌是印度女性中最常见的癌症,并且是全世界女性死亡的主要原因。宫颈癌由肿瘤前的宫颈上皮内瘤变(CIN)发展而来。进行这项研究以评估端粒酶活性作为一种肿瘤标志物,以检测CIN和宫颈癌患者的癌症。将结果与人乳头瘤病毒(HPV)的状态,临床分期和组织病理学研究进行了比较。方法:采用基于PCR的端粒重复扩增方案(TRAP)检测可疑宫颈癌患者宫颈常规打孔活检收集的宫颈组织中端粒酶活性。在包括对照组在内的所有研究组中均确定了高危(HR)HPV-16和-18状态。共研究了125例患者(包括50例CIN患者和75例宫颈癌患者(包括9例腺鳞癌患者))和22例对照组。计算了检测CIN和宫颈癌的敏感性和特异性。结果:CIN I,II和III级患者的端粒酶阳性率分别为17%,33%和57%。在子宫颈癌患者中,早期临床阶段(Ia-IIb)的患者端粒酶活性显示68%的阳性率,而晚期临床阶段的患者则显示92%的阳性率。在本研究中,端粒酶阳性与HR HPV-16和-18的检测显着相关(p <0.001)。作为诊断测试,除了使用端粒酶活性作为诊断测试的晚期癌症患者外,上述分析均未将灵敏度≥90%和特异性≥90%相结合。结论:我们的发现提示端粒酶激活是宫颈癌发生中的一个相对较早的事件,并且与宫颈病变的等级,HR-HPV的状态(16和18个亚型)以及临床分期有关。因此,这些关联提示它可能是检测宫颈癌的可能靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号